

PATENT APPLICATION

**PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS
AND OTHER DISEASES WITH IMMUNOEFFECTOR COMPOUNDS**

Inventor(s): Jory R. Baldridge, a citizen of The United States, residing at
1862 Mountain Meadow Lane
Victor, MT 59875

David A. Johnson, a citizen of The United States, residing at
121 Woodland Way
Hamilton, MT 59840

Christopher W. Cluff, a citizen of The United States, residing at
516 South 6th Street
Hamilton, MT 58940

Assignee: Corixa Corporation
1124 Columbia Street, Suite 200
Seattle, WA 98104

Entity: Large

PATENT APPLICATION

PROPHYLACTIC AND THERAPEUTIC TREATMENT OF INFECTIOUS AND OTHER
DISEASES WITH IMMUNOEFFECTOR COMPOUNDS

5 BACKGROUND OF THE INVENTION

The innate immune system coordinates the inflammatory response to pathogens by a system that discriminates between self and non-self via receptors that identify classes of molecules synthesized exclusively by microbes. These classes are sometimes referred to as pathogen associated molecular patterns (PAMPs) and include, for example, lipopolysaccharide (LPS), peptidoglycans, lipotechoic acids, and bacterial lipoproteins (BLPs).

LPS, an abundant outer cell-wall constituent from gram-negative bacteria, is recognized by the innate immune system. Although the chemical structure of LPS has been known for some time, the molecular basis of recognition of LPS by serum proteins and/or cells is only now being elucidated. In a series of recent reports, a family of receptors, referred to as Toll-like receptors (TLRs), have been linked to the potent innate immune response to LPS and other microbial components. TLR are membrane proteins having a single transmembrane domain. The cytoplasmic domains are approximately 200 amino acids and share similarity with the cytoplasmic domain of the IL-1 receptor. The extracellular domains are relatively large (about 550-980 amino acids) and may contain multiple ligand-binding sites.

The importance of TLRs in the immune response to LPS has been specifically demonstrated for at least two Toll-like receptors, Tlr2 and Tlr4. For example, transfection studies with embryonic kidney cells revealed that human Tlr2 was sufficient to confer responsiveness to LPS (Yang et al., *Nature* 395:284-288 (1998); Kirschning et al. *J Exp Med.* 11:2091-97 (1998)). A strong response by LPS appeared to require both the LPS-binding protein (LBP) and CD14, which binds LPS with high affinity. Direct binding of LPS to Tlr2 was observed at a relatively low affinity, suggesting that accessory proteins may facilitate binding and/or activation of Tlr2 by LPS in vivo.

The importance of Tlr4 in the immune response to LPS was demonstrated in conjunction with positional cloning in *lps* mutant mouse strains. Two mutant alleles of the mouse *lps* gene have been identified, a semidominant allele that arose in the C3H/HeJ strain and a second, recessive allele that is present in the C57BL/10ScN and C57BL/10ScCr strains. Mice that are homozygous for mutant alleles of *lps* are sensitive to infection by Gram-negative bacteria and are resistant to LPS-induced septic shock. The *lps* locus from these strains was cloned and it was demonstrated that the mutations altered the mouse Tlr4 gene in both instances (Portorak et al., *Science* 282:2085-2088 (1998); Qureshi et al., *J Exp Med* 4:615-625 (1999)). It was concluded from these reports that Tlr4 was required for a response to LPS.

The biologically active endotoxic sub-structural moiety of LPS is lipid-A, a phosphorylated, multiply fatty-acid-acylated glucosamine disaccharide that serves to anchor the entire structure in the outer membrane of Gram-negative bacteria. We previously reported that the toxic effects of lipid A could be ameliorated by selective chemical modification of lipid A to produce monophosphoryl lipid A compounds (MPL® immunostimulant; Corixa Corporation; Seattle, WA). Methods of making and using MPL® immunostimulant, and structurally like compounds, for vaccine adjuvant and other applications have been described (see, for example, U.S. Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094; 4,987,237; Johnson et al., *J Med Chem* 42:4640-4649 (1999); Ulrich and Myers, in *Vaccine Design: The Subunit and Adjuvant Approach*; Powell and Newman, Eds.; Plenum: New York, 495-524, 1995). In particular, these and other references demonstrated that MPL® immunostimulant and related compounds had significant adjuvant activities for enhancing humoral and/or cell-mediated immunity to the antigens, when used in vaccine formulations with protein and carbohydrate antigens.

Synthetic mono- and disaccharide molecules which share structural similarities with MPL® immunostimulant, referred to as aminoalkyl glucosaminide phosphates (AGPs), have been described, see for example, U.S. Patent No. 6,113,918, U.S. Patent No. 6,303,347, and WO 98/50399, published October 12, 1998. These compounds retain significant adjuvant characteristics when formulated with antigens in vaccine compositions and have similar or improved toxicity profiles when compared with monophosphoryl lipid A. These compounds


have been described for use in combination with antigens in vaccine formulations (U.S. Patent No. 6,113,918) and in the absence of antigen, as monotherapies, WO 01/90129, published 29-Nov-2001.

Cyclic aminoalkyl glucosaminide phosphates or "cyclic AGPs" have been described in PCT Patent Application No. PCT/US01/24284. These cyclic AGPs are effective immunoeffector molecules which enhance humoral and cell-mediated immune responses to vaccine antigens. As used herein, the term "cyclic AGP" means an azacycloalkyl or (azacycloalkyl)alkyl glucosaminide phosphate, wherein a 2-deoxy-2-amino-b-D-glucopyranose (glucosamine) is glycosidically linked to an azacycloalkyl or (azacycloalkyl)alkyl (aglycon) group.

The present invention provides monotherapies formulated and administered in the absence of exogenous antigens for the prophylactic and/or therapeutic treatment of plant and animal diseases and conditions, such as infectious diseases, autoimmunity and allergies. The monotherapies of the present invention comprise one or more cyclic AGPs. These and other aspects of the invention will become evident upon reference to the following detailed description and the attached drawings.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides methods for treating, ameliorating or substantially preventing a disease or condition in an animal by administering an effective amount of a compound having the formula (I):




(I)

and pharmaceutically acceptable salts thereof, wherein X is -O- or -NH- and Y is -O- or -S-; R^1 , R^2 , and R^3 are each independently a (C_2-C_{20}) acyl group, including saturated, unsaturated and branched acyl groups; R^4 is -H or $-PO_3R^7R^8$, wherein R^7 and R^8 are each independently H or (C_1-C_4) aliphatic groups; R^5 is -H, $-CH_3$ or $-PO_3R^9R^{10}$, wherein R^9 and R^{10} are each independently selected from -H and (C_1-C_4) aliphatic groups; R^6 is independently selected from H, OH, (C_1-C_4) oxyaliphatic groups, $-PO_3R^{11}R^{12}$, $-OPO_3R^{11}R^{12}$, $-SO_3R^{11}$, $-OSO_3R^{11}$, $-NR^{11}R^{12}$, $-SR^{11}$, $-CN$, $-NO_2$, $-CHO$, $-CO_2R^{11}$, and $-CONR^{11}R^{12}$, wherein R^{11} and R^{12} are each independently selected from H and (C_1-C_4) aliphatic groups; with the provisos that one of R^4 and R^5 is a phosphorus-containing group and that when R^4 is $-PO_3R^7R^8$, R^5 is other than $-PO_3R^9R^{10}$, wherein “*1-3” and “**” represent chiral centers; wherein the subscripts n, m, p and q are each independently an integer from 0 to 6, with the proviso that the sum of p and m is from 0 to 6.

In some embodiments, the compounds of the present invention contain an -O- at X and Y, R^4 is $PO_3R^7R^8$, R^5 and R^6 are H, and the subscripts n, m, p, and q are integers from 0 to 3. In a more preferred embodiment, R^7 and R^8 are -H. In one embodiment, subscript n is 1, subscript m is 2, and subscripts p and q are 0. In other embodiments, R_1 , R_2 , and R_3 are (C_6-C_{14})


[illegible]

Illustrative embodiments include *N*-[(*R*)-3-tetradecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinymethyl 2-deoxy-4-*O*-phosphono-2-[(*R*)-3-tetradecanoyloxytetradecanoylamino]-3-*O*-[(*R*)-3-tetradecanoyloxytetradecanoyl]- β -D-glucopyranoside and pharmaceutically acceptable salts thereof; Formula II,




(II)

N-[(*R*)-3-dodecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-phosphono-2-[(*R*)-3-dodecanoyloxytetradecanoylamino]-3-*O*-[(*R*)-3-dodecanoyloxytetradecanoyl]-β-D-glucopyranoside and pharmaceutically acceptable salts thereof; Formula III,



(III)

and *N*-[(*R*)-3-decanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-phosphono-2-[(*R*)-3-decanoyloxytetradecanoylamino]-3-*O*-[(*R*)-3-decanoyloxytetradecanoyl]-β-*D*-glucopyranoside and pharmaceutically acceptable salts thereof; Formula IV.



(IV)

In certain illustrative aspects of the invention, the above methods are employed in treating, ameliorating or substantially preventing infectious diseases, autoimmune diseases and allergies.

The present invention, in other aspects, provides pharmaceutical compositions comprising one or more of the compounds described above in a suitable excipient, formulated and/or administered in the absence of exogenous antigen.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS OF THE INVENTION

ILLUSTRATIVE PROPHYLACTIC AND THERAPEUTIC APPLICATIONS

The present invention broadly concerns prophylactic and therapeutic methods of treating certain diseases and other medical conditions by administration of an effective amount

of one or more compounds described herein or a pharmaceutical composition comprising one or more such compounds. While certain of the cyclic AGP compounds have been described for use as adjuvants in combination with exogenously administered antigens in vaccine formulations, and for use in certain other applications, the present invention provides novel therapeutic methods that employ the compounds preferably in monotherapeutic applications, *i.e.*, in the absence of exogenously administered antigen.

In one aspect the present invention provides methods for treating, ameliorating and/or substantially preventing infectious diseases in eukaryotic subjects, particularly in animals, preferably in humans. Given the importance of TLR-mediated signalling in the innate immune response to microbial challenge, the ability to stimulate such pathways selectively and with minimal toxicity represents a powerful approach for prophylactic and/or therapeutic treatment modalities against a wide range of infectious agents.

The methods described herein are applicable against essentially any type of infectious agent, including bacteria, viruses, parasites, and fungi. Illustratively, the invention is useful for the prophylactic and/or therapeutic treatment of bacterial infections by species from *Pseudomonas*, *Escherichia*, *Klebsiella*, *Enterobacter*, *Proteus*, *Serratia*, *Candida*, *Staphylococci*, *Streptococci*, *Chlamydia*, *Mycoplasma*, *Bacillus*, and numerous others. Illustrative viral conditions that may be treated in accordance with the invention include those caused, for example, by Influenza viruses, Adenoviruses, parainfluenza viruses, Rhinoviruses, respiratory syncytial viruses (RSVs), Herpes viruses, Cytomegaloviruses, Hepatitis viruses, *e.g.*, Hepatitis B and C viruses, and others. Illustrative fungi include, for example, *Aspergillus*, *Candida albicans*, *Cryptococcus neoformans*, *Coccidioides immitis*, and others.

In one illustrative embodiment, the invention provides methods for the treatment of subjects, particularly immunocompromised subjects, that have developed or are at risk for developing infections, such as nosocomial bacterial and viral infections. About 2 million of the 40 million individuals hospitalized every year develop nosocomial infection during their stay and about 1% of these, or about 400,000 patients, develop nosocomial pneumonia, more than 7000 of which die. This makes nosocomial pneumonia the leading cause of death in hospital-acquired

infections. Thus, this embodiment fills a significant need for effective prophylactic approaches in the treatment of nosocomial infections.

In a related embodiment, the present invention provides prophylactic treatments for immunocompromised patients, such as HIV-positive patients, who have developed or are at risk for developing pneumonia from either an opportunistic infection or from the reactivation of a suppressed or latent infection. In 1992, about 20,000 cases of *Pneumocystis carinii* infections in AIDS patients were reported in the U.S. alone. Additionally, 60-70% of all AIDS patients get *P. carinii* at some time during their illness. Thus, the present invention in this embodiment provides effective prophylactic methods for this at-risk population.

In another related embodiment, the methods of the present invention are used for treating other patient populations that may be immunocompromised and/or at risk for developing infectious diseases, including, for example, patients with cystic fibrosis, chronic obstructive pulmonary disease and other immunocompromized and/or institutionalized patients.

In another aspect of the invention, the compounds described herein are employed in methods for treating, ameliorating or substantially preventing allergic disorders and conditions, such as sinusitis, chronic rhinosinusitis, asthma, atopic dermatitis and psoriasis. This approach is based at least in part on the ability of the compounds to activate the production of cytokines from target cells that can compete with stereotypic allergic-type cytokine responses characterized by IL-4 production or hyperresponsiveness to IL-4 activity. Administration of certain of the compounds disclosed herein results in IFN-gamma and IL-12 expression from antigen processing and presenting cells, as well as other cells, resulting in down regulation of cytokines associated with allergic responses such as IL-4, 5, 6, 10 and 13.

In another aspect of the invention, compounds are employed in methods for treating autoimmune diseases and conditions. The compounds for use in this embodiment will typically be selected from those capable of antagonizing, inhibiting or otherwise negatively modulating one or more Toll-like receptors, particularly Tlr2 and/or Tlr4, such that an autoimmune response associated with a given condition is ameliorated or substantially prevented. Illustratively, the methods provided by this embodiment can be used in the treatment


of conditions such as inflammatory bowel disease, rheumatoid arthritis, chronic arthritis, multiple sclerosis and psoriasis.

While not wishing to be bound by theory, it is believed that the efficacy of the prophylactic and therapeutic applications described above are based at least in part on the involvement of the compounds in the modulation of Toll-like receptor activity. In particular, Toll-like receptors Tlr2, Tlr4, and others, are believed to be specifically activated, competitively inhibited or otherwise affected by the non-toxic LPS derivatives and mimetics disclosed herein. Accordingly, the methods of the invention provide a powerful and selective approach for modulating the innate immune response pathways in animals without giving rise to the toxicities often associated with the native bacterial components that normally stimulate those pathways .

10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1870
1871
1872
1873
1874
1875
1876
1877
1878
1879
1880
1881
1882
1883
1884
1885
1886
1887
1888
1889
1890
1891
1892
1893
1894
1895
1896
1897
1898
1899
1900
1901
1902
1903
1904
1905
1906
1907
1908
1909
1910
1911
1912
1913
1914
1915
1916
1917
1918
1919
1920
1921
1922
1923
1924
1925
1926
1927
1928
1929
1930
1931
1932
1933
1934
1935
1936
1937
1938
1939
1940
1941
1942
1943
1944
1945
1946
1947
1948
1949
1950
1951
1952
1953
1954
1955
1956
1957
1958
1959
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
2037
2038
2039
2040
2041
2042
2043
2044
2045
2046
2047
2048
2049
2050
2051
2052
2053
2054
2055
2056
2057
2058
2059
2060
2061
2062
2063
2064
2065
2066
2067
2068
2069
2070
2071
2072
2073
2074
2075
2076
2077
2078
2079
2080
2081
2082
2083
2084
2085
2086
2087
2088
2089
2090
2091
2092
2093
2094
2095
2096
2097
2098
2099
2100
2101
2102
2103
2104
2105
2106
2107
2108
2109
2110
2111
2112
2113
2114
2115
2116
2117
2118
2119
2120
2121
2122
2123
2124
2125
2126
2127
2128
2129
2130
2131
2132
2133
2134
2135
2136
2137
2138
2139
2140
2141
2142
2143
2144
2145
2146
2147
2148
2149
2150
2151
2152
2153
2154
2155
2156
2157
2158
2159
2160
2161
2162
2163
2164
2165
2166
2167
2168
2169
2170
2171
2172
2173
2174
2175
2176
2177
2178
2179
2180
2181
2182
2183
2184
2185
2186
2187
2188
2189
2190
2191
2192
2193
2194
2195
2196
2197
2198
2199
2200
2201
2202
2203
2204
2205
2

ILLUSTRATIVE CYCLIC AGP COMPOUNDS

Illustrative compounds employed in the above prophylactic and therapeutic applications comprise compounds of Formula I:



(I)


and pharmaceutically acceptable salts thereof, wherein X is -O- or -NH- and Y is -O- or -S- ; R^1 , R^2 , and R^3 are each independently a (C_2 - C_{20})acyl group, including saturated, unsaturated and branched acyl groups; R^4 is -H or $-PO_3R^7R^8$, wherein R^7 and R^8 are each independently H or (C_1 - C_4)aliphatic groups; R^5 is -H, - CH_3 or $-PO_3R^9R^{10}$, wherein R^9 and R^{10} are each independently selected from -H and (C_1 - C_4)aliphatic groups; R^6 is independently selected from H, OH, (C_1 - C_4)oxyaliphatic groups, $-PO_3R^{11}R^{12}$, $-OPO_3R^{11}R^{12}$, $-SO_3R^{11}$, $-OSO_3R^{11}$, $-NR^{11}R^{12}$, $-SR^{11}$, -CN, $-NO_2$, -CHO, $-CO_2R^{11}$, and $-CONR^{11}R^{12}$, wherein R^{11} and R^{12} are each independently selected from H and (C_1 - C_4)aliphatic groups; with the provisos that one of R^4 and R^5 is a phosphorus-containing group and that when R^4 is $-PO_3R^7R^8$, R^5 is other than $-PO_3R^9R^{10}$, wherein “*1-3,” and “**” represent chiral centers; wherein the subscripts n, m, p and q

are each independently an integer from 0 to 6, with the proviso that the sum of p and m is from 0 to 6.

5 Although the hexopyranoside in Formula I is shown in the gluco configuration, other glycosides are within the scope of the invention. For example, glycopyranosides, including other hexopyranosides (e.g., allo, altro, manno, gulo, ido, galacto, talo), are within the scope of the invention.

10 In the general formula above, the configuration of the 3'-stereogenic centers to which the normal fatty acyl residues are attached, denoted "*1", "*2" and "* 3", is *R* or *S*, but preferably *R*. The absolute stereochemistry of the carbon atoms of the cyclic aglycon unit to which R⁶ and the glucosamine unit are attached, directly or indirectly (denoted "**") can be *R* or *S*. In the general formula above, Y can be in the equatorial or axial position, but is preferably equatorial. All stereoisomers, enantiomers, diastereomers and mixtures thereof are considered to be within the scope of the present invention.

In illustrative embodiments of the present invention X and Y are $-O-$, R^4 is phosphono, R^5 and R^6 are H, and the subscripts n, m, p, and q are integers of from 0 to 3, and more preferably 0 to 2. In an exemplary embodiment the integer n is 1, the integer m is 2, and integers p and q are 0. In this embodiment, the compounds of this invention are 2-pyrrolidinylmethyl β -D-glucosaminide 4-phosphates having the general formula (V):




(V)

In another illustrative embodiment of the present invention, R_1 , R_2 , and R_3 of formula (III) are tetradecanoyl residues and the configuration of the 3'-stereogenic centers ("*1-3") to which they are attached is *R*, Y is in the equatorial position, and the absolute stereochemistry of the pyrrolidine stereogenic center ("**") is *S*.


Other exemplary embodiments include *N*-[(*R*)-3-tetradecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-phosphono-2-[(*R*)-3-tetradecanoyloxytetradecanoylamino] -3-*O*-[(*R*)-3-tetradecanoyloxytetradecanoyl]- β-D-glucopyranoside, and its pharmaceutically acceptable salts, formula (II):

5



(II)


N-[(*R*)-3-dodecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-phosphono-2-[(*R*)-3-dodecanoyloxytetradecanoylamino]-3-*O*-[(*R*)-3-dodecanoyloxytetradecanoyl]- β -D-glucopyranoside and pharmaceutically acceptable salts thereof; Formula III,



(III)

and *N*-[*(R)*-3-decanoyloxytetradecanoyl]-*(S)*-2-pyrrolidinylmethyl 2-deoxy-4-*O*-phosphono-2-[[*(R)*-3-decanoyloxytetradecanoylamino]-3-*O*-[[*(R)*-3-decanoyloxytetradecanoyl]-β-D-glucopyranoside and pharmaceutically acceptable salts thereof; Formula IV.

5



The compounds of the present invention can be prepared using methods outlined in Johnson et al., *Bioorg. Med. Chem. Lett.* 9:2273, 1999 and PCT/WO98/50399 and references therein. In general, the synthetic methods described in the above noted reference are broadly applicable to the preparation of compounds having different acyl groups and subdivisions. For example, certain compounds useful in the present invention are described in U.S. Provisional Application No. 60/223,056 and International application PCT/US01/24284. In general, the synthetic methods described in the above-noted references described herein and other synthetic methods otherwise familiar in the art are broadly applicable to the preparation these compounds. For example, in making compounds having different acyl groups and substitutions, one of skill in the art will appreciate that the convergent methods described therein can be modified to use alternate acylating agents, or can be initiated with commercially available materials having appropriate acyl groups attached.

The term "acyl" refers to those groups derived from an aliphatic organic acid by removal of the hydroxy portion of the acid. Accordingly, acyl is meant to include, for example, acetyl, propionyl, butyryl, decanoyl, and pivaloyl.

A "(C₂-C₂₀)acyl" is an acyl group having from 2 to 20 carbons. Similarly, a (C₆-C₁₄), (C₆-C₁₂), (C₉-C₁₂), and (C₆-C₈)acyl are acyl groups having from 6 to 14 carbons, from 6 to 12 carbons, from 9 to 12 carbons, and from 6 to 8 carbons, respectively. Also included within the term "acyl" are such groups having typical substituents such as hydroxy, keto, etc.

The term 'aliphatic' by itself or as part of another substituent, means, unless otherwise stated, a straight or branched chain or cyclic, hydrocarbon moiety, including a moiety that contains both cyclical and chain elements, which may be fully saturated or mono- or polyunsaturated, having the number of carbon atoms designated (*i.e.* C₁-C₄ means one to four carbons). Examples of saturated hydrocarbon moieties include groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, t-butyl, isobutyl, sec-butyl, cyclopropyl, cyclopropylmethyl, methylene, ethylene, and n-butylene. An unsaturated alkyl group is one having one or more double and/or triple bonds. Examples of unsaturated alkyl groups include vinyl, 2-propenyl, crotyl, 1-propynyl and 2-(butadienyl).

The term "oxyaliphatic" refers to those groups having an aliphatic group attached to the remainder of the molecule through an oxygen atom.

Each of the above terms (*e.g.*, "aliphatic," "acyl") are meant to include both substituted and unsubstituted forms of the indicated moiety. Preferred substituents for each type of group are provided below.

Substituents for the aliphatic groups can be a variety of groups selected from: -OR', =O, =S, =NR', =N-OR', -NR'R'', -SR', -halogen, -SiR'R''R''', -OC(O)R', -C(O)R', -CO₂R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R''', -NR''C(O)₂R', -NH-C(NH₂)=NH, -NR'C(NH₂)=NH, -NH-C(NH₂)=NR', -S(O)R', -S(O)₂R', -S(O)₂NR'R'', -CN and -NO₂ in a number ranging from zero to (2m'+1), where m' is the total number of carbon atoms in such radical. R', R'' and R''' each independently refer to hydrogen and unsubstituted (C₁-C₈)aliphatic groups. When R' and R'' are attached to the same nitrogen atom, they can be combined with the nitrogen atom to form a 5-, 6-, or 7-membered ring. For example, -NR'R'' is

meant to include 1-pyrrolidinyl and 4-morpholinyl. From the above discussion of substituents, one of skill in the art will understand that the term "aliphatic" is meant to include groups such as haloalkyl (e.g., -CF₃ and -CH₂CF₃) and the like.

The terms "halo" or "halogen," by themselves or as part of another substituent, mean, unless otherwise stated, a fluorine, chlorine, bromine, or iodine atom. In compounds having halogen substituents, the halogens may be the same or different.

The term "pharmaceutically acceptable salts" is meant to include salts of the active compounds which are prepared with relatively nontoxic acids or bases, depending on the particular substituents found on the compounds described herein. When compounds of the present invention contain relatively acidic functionalities, base addition salts can be obtained by addition of the desired base, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino, or magnesium salt, or a similar salt. When compounds of the present invention contain relatively basic functionalities, acid addition salts can be obtained by addition of the desired acid, either neat or in a suitable inert solvent. Examples of pharmaceutically acceptable acid addition salts include those derived from inorganic acids like hydrochloric, hydrobromic, nitric, carbonic, monohydrogencarbonic, phosphoric, monohydrogenphosphoric, dihydrogenphosphoric, sulfuric, monohydrogensulfuric, hydriodic, or phosphorous acids and the like, as well as the salts derived from relatively nontoxic organic acids like acetic, propionic, isobutyric, oxalic, maleic, malonic, benzoic, succinic, suberic, fumaric, mandelic, phthalic, benzenesulfonic, p-tolylsulfonic, citric, tartaric, methanesulfonic, and the like. Also included are salts of amino acids such as arginate and the like, and salts of organic acids like glucuronic or galactunoric acids and the like (see, for example, Berge, S.M., *et al.*, "Pharmaceutical Salts", *Journal of Pharmaceutical Science*, 1977, 66, 1-19). Certain specific compounds of the present invention contain both basic and acidic functionalities that allow the compounds to be converted into either base or acid addition salts.

The neutral forms of the compounds may be regenerated by contacting the salt with a base or acid and isolating the parent compound in the conventional manner. The parent form of the compound differs from the various salt forms in certain physical properties, such as

solubility in polar solvents, but otherwise the salts are equivalent to the parent form of the compound for the purposes of the present invention.

In addition to salt forms, the present invention provides compounds which are in a prodrug form. Prodrugs of the compounds described herein are those compounds that readily undergo chemical changes under physiological conditions to provide the compounds of the present invention. Additionally, prodrugs can be converted to the compounds of the present invention by chemical or biochemical methods in an *ex vivo* environment. For example, prodrugs can be slowly converted to the compounds of the present invention when placed in a transdermal patch reservoir with a suitable enzyme or chemical reagent.

Certain compounds of the present invention can exist in unsolvated forms as well as solvated forms, including hydrated forms. In general, the solvated forms are equivalent to unsolvated forms and are intended to be encompassed within the scope of the present invention. Certain compounds of the present invention may exist in multiple crystalline or amorphous forms. In general, all physical forms are equivalent for the uses contemplated by the present invention and are intended to be within the scope of the present invention.

Certain compounds of the present invention possess asymmetric carbon atoms (optical centers) or double bonds; the racemates, diastereomers, geometric isomers and individual isomers are all intended to be encompassed within the scope of the present invention.

The compounds of the present invention may also contain unnatural proportions of atomic isotopes at one or more of the atoms that constitute such compounds. For example, the compounds may be radiolabeled with radioactive isotopes, such as for example tritium (^3H), iodine-125 (^{125}I) or carbon-14 (^{14}C). All isotopic variations of the compounds of the present invention, whether radioactive or not, are intended to be encompassed within the scope of the present invention.

ILLUSTRATIVE PHARMACEUTICAL COMPOSITIONS AND THEIR DELIVERY

In another embodiment, the present invention concerns pharmaceutical compositions comprising one or more of the compounds formulated and administered in the absence of exogenous antigen, *i.e.*, are used in monotherapeutic applications, in combination with pharmaceutically-acceptable carriers or excipients. Such pharmaceutical compositions are

useful for administration to a cell, tissue, animal or plant, either alone, or in combination with one or more other modalities of therapy. For many such embodiments, the pharmaceutical compositions of the invention will comprise one or more of the compounds described herein.

The phrase "pharmaceutically acceptable" refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human. As used herein, "carrier" or "excipient" includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated.

Illustrative carriers for use in formulating the pharmaceutical compositions include, for example, oil-in-water or water-in-oil emulsions, aqueous compositions with or without inclusion of organic co-solvents suitable for intravenous (IV) use, liposomes or surfactant-containing vesicles, microspheres, microbeads and microsomes, powders, tablets, capsules, suppositories, aqueous suspensions, aerosols, and other carriers apparent to one of ordinary skill in the art.

In certain embodiments, the pharmaceutical compositions will comprise one or more buffers (e.g., neutral buffered saline or phosphate buffered saline), carbohydrates (e.g., glucose, mannose, sucrose or dextrans), mannitol, proteins, polypeptides or amino acids such as glycine, antioxidants, bacteriostats, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide), solutes that render the formulation isotonic, hypotonic or weakly hypertonic with the blood of a recipient, suspending agents, thickening agents and/or preservatives.

For certain applications, aqueous formulations will be preferred, particularly those comprising an effective amount of one or more surfactants. For example, the composition can be in the form of a micellar dispersion comprising at least one suitable surfactant, e.g., a phospholipid surfactant. Illustrative examples of phospholipids include diacyl phosphatidyl glycerols, such as dimyristoyl phosphatidyl glycerol (DPMG), dipalmitoyl phosphatidyl glycerol

(DPPG), and distearoyl phosphatidyl glycerol (DSPG), diacyl phosphatidyl cholines, such as dimyristoyl phosphatidylcholine (DPMC), dipalmitoyl phosphatidylcholine (DPPC), and distearoyl phosphatidylcholine (DSPC); diacyl phosphatidic acids, such as dimyristoyl phosphatidic acid (DPMA), dipalmitoyl phosphatidic acid (DPPA), and distearoyl phosphatidic acid (DSPA); and diacyl phosphatidyl ethanolamines such as dimyristoyl phosphatidyl ethanolamine (DPME), dipalmitoyl phosphatidyl ethanolamine (DPPE) and distearoyl phosphatidyl ethanolamine (DSPE). Typically, a surfactant:mono-/disaccharide molar ratio in an aqueous formulation will be from about 10:1 to about 1:10, more typically from about 5:1 to about 1:5, however any effective amount of surfactant may be used in an aqueous formulation to best suit the specific objectives of interest.

As used herein, "an effective amount" is that amount which shows a response over and above the vehicle or negative controls. As discussed above, the precise dosage of the compound of the subject invention to be administered to a patient will depend the route of administration, the pharmaceutical composition, and the patient.

The compounds and pharmaceutical compositions of the invention can be formulated for essentially any route of administration, *e.g.*, injection, inhalation by oral or intranasal routes, rectal, vaginal or intratracheal instillation, ingestion, or transdermal or transmucosal routes, and the like. In this way, the therapeutic effects attainable by the methods and compositions of the invention can be, for example, systemic, local, tissue-specific, etc., depending of the specific needs of a given application of the invention.

Illustrative formulations can be prepared and administered parenterally, *i.e.*, intraperitoneally, subcutaneously, intramuscularly or intravenously. One illustrative example of a carrier for intravenous use includes a mixture of 10% USP ethanol, 40% USP propylene glycol or polyethylene glycol 600 and the balance USP Water for Injection (WFI). Other illustrative carriers include 10% USP ethanol and USP WFI; 0.01-0.1% triethanolamine in USP WFI; or 0.01-0.2% dipalmitoyl diphosphatidylcholine in USP WFI; and 1-10% squalene or parenteral vegetable oil-in-water emulsion. Pharmaceutically acceptable parenteral solvents will generally be selected such that they provide a solution or dispersion which may be filtered through a 0.22 micron filter without removing the active ingredient.

Illustrative examples of carriers for subcutaneous or intramuscular use include phosphate buffered saline (PBS) solution, 5% dextrose in WFI and 0.01-0.1% triethanolamine in 5% dextrose or 0.9% sodium chloride in USP WFI, or a 1 to 2 or 1 to 4 mixture of 10% USP ethanol, 40% propylene glycol and the balance an acceptable isotonic solution such as 5% dextrose or 0.9% sodium chloride; or 0.01-0.2% dipalmitoyl diphosphatidylcholine in USP WFI and 1 to 10% squalene or parenteral vegetable oil-in-water emulsions.

Examples of carriers for administration via mucosal surfaces depend upon the particular route, e.g., oral, sublingual, intranasal, etc. When administered orally, illustrative examples include pharmaceutical grades of mannitol, starch, lactose, magnesium stearate, sodium saccharide, cellulose, magnesium carbonate and the like, with mannitol being preferred. When administered intranasally, illustrative examples include polyethylene glycol, phospholipids, glycols and glycolipids, sucrose, and/or methylcellulose, powder suspensions with or without bulking agents such as lactose and preservatives such as benzalkonium chloride, EDTA. In a particularly illustrative embodiment, the phospholipid 1,2 dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) is used as an isotonic aqueous carrier at about 0.01-0.2% for intranasal administration of the compound of the subject invention at a concentration of about 0.1 to 3.0 mg/ml.

When administered by inhalation, illustrative carriers include polyethylene glycol or glycols, DPPC, methylcellulose, powdered dispersing agents, and preservatives, with polyethylene glycols and DPPC being preferred. In many instances, it will be preferred that the compounds be in a nebulized form when administration by inhalation. Illustratively, delivery may be by use of a single-use delivery device, a mist nebulizer, a breath-activated powder inhaler, an aerosol metered-dose inhaler (MDI) or any other of the numerous nebulizer delivery devices available in the art. Additionally, mist tents or direct administration through endotracheal tubes may also be used. Delivery via an intratracheal or nasopharyngeal mode will be efficacious for certain indications.

One skilled in this art will recognize that the above description is illustrative rather than exhaustive. Indeed, many additional formulations techniques and pharmaceutically-acceptable excipients and carrier solutions are well-known to those skilled in the art, as is the

development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens.

The compounds can be evaluated in a variety of assay formats, including those described herein, to identify and select those having the characteristics best suited for a given application of the invention. For example, animal models can be used for identifying and evaluating cytokine release profiles into systemic circulation following administration of a cyclic AGP compound. In addition, various *in vitro* and *in vivo* models exist for examining changes in one or more aspects of an immune response to different antigenic components in order to identify compounds best suited for eliciting a specific immune response of interest. For example, a compound can be contacted with target cells, such as macrophages, dendritic cells or Langerhans cells *in vitro*, and elaborated cytokines can be measured. In addition, gene expression arrays can be used to identify specific pathways activated or inhibited by a particular cyclic AGP of interest.

It will be understood that, if desired, the compounds disclosed herein may be administered in combination with other therapeutic modalities, such as antimicrobial, antiviral and antifungal compounds or therapies, various DNA-based therapeutics, RNA-based therapeutics, polypeptide-based therapeutics, and/or with other immunoeffectors. In fact, essentially any other component may also be included, given that the additional component(s) do not cause a significant adverse effect upon contact with the target cells or host tissues. The compositions may thus be delivered along with various other agents as required or desired for the specific embodiment(s) of the invention being implemented.

Illustratively, the pharmaceutical compositions of the invention can include, or be used in conjunction with, DNA encoding one or more therapeutic proteins, antisense RNAs, ribozymes or the like. The DNA may be present within any of a variety of delivery systems known to those of ordinary skill in the art, including nucleic acid expression systems, bacteria and viral expression systems. Numerous gene delivery techniques are well known in the art, such as those described by Rolland, *Crit. Rev. Therap. Drug Carrier Systems* 15:143-198, 1998, and references cited therein. Appropriate nucleic acid expression systems contain the necessary DNA sequences for expression in the patient (such as a suitable promoter and terminating

signal). In a preferred embodiment, the DNA may be introduced using a viral expression system (e.g., vaccinia or other pox virus, retrovirus, or adenovirus), which may involve the use of a non-pathogenic (defective), replication competent virus. Suitable systems are disclosed, for example, in Fisher-Hoch et al., *Proc. Natl. Acad. Sci. USA* 86:317-321, 1989; Flexner et al., *Ann. N.Y. Acad. Sci.* 569:86-103, 1989; Flexner et al., *Vaccine* 8:17-21, 1990; U.S. Patent Nos. 4,603,112, 4,769,330, and 5,017,487; WO 89/01973; U.S. Patent No. 4,777,127; GB 2,200,651; EP 0,345,242; WO 91/02805; Berkner, *Biotechniques* 6:616-627, 1988; Rosenfeld et al., *Science* 252:431-434, 1991; Kolls et al., *Proc. Natl. Acad. Sci. USA* 91:215-219, 1994; Kass-Eisler et al., *Proc. Natl. Acad. Sci. USA* 90:11498-11502, 1993; Guzman et al., *Circulation* 88:2838-2848, 1993; and Guzman et al., *Cir. Res.* 73:1202-1207, 1993. Techniques for incorporating DNA into such expression systems are well known to those of ordinary skill in the art.

The DNA may also be "naked," as described, for example, in Ulmer et al., *Science* 259:1745-1749, 1993 and reviewed by Cohen, *Science* 259:1691-1692, 1993. The uptake of naked DNA may be increased by coating the DNA onto biodegradable beads, which are efficiently transported into the cells. It will be apparent that a pharmaceutical composition of the invention may comprise both a polynucleotide and a protein component.

Any of a variety of additional immunostimulants may be included in the compositions of this invention. For example, cytokines, such as GM-CSF, interferons or interleukins to further modulate an immune response of interest. For example, in certain embodiments, additional components may be included in the compositions to further enhance the induction of high levels of Th1-type cytokines (e.g., IFN- γ , TNF α , IL-2 and IL-12). Alternatively, or in addition, high levels of Th2-type cytokines (e.g., IL-4, IL-5, IL-6 and IL-10) may be desired for certain therapeutic applications. The levels of these cytokines may be readily assessed using standard assays. For a review of the families of cytokines, see Mosmann and Coffman, *Ann. Rev. Immunol.* 7:145-173, 1989.

Illustrative compositions for use in induction of Th1-type cytokines include, for example, a combination of CpG-containing oligonucleotides (in which the CpG dinucleotide is unmethylated) as described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and 5,856,462. Immunostimulatory DNA sequences are also described, for example,

by Sato et al., *Science* 273:352, 1996. Other suitable immunostimulants comprise saponins, such as QS21 (Aquila Biopharmaceuticals Inc., Framingham, MA), GPI-100 (Marciani et al., *Vaccine* 18:3141, 2000, U.S. Patent No. 6,080,725) and related saponin derivatives and mimetics thereof.

Other illustrative immunostimulants that can be used in conjunction with the present invention include Montanide ISA 720 (Seppic, France), SAF (Chiron, California, United States), ISCOMS (CSL), MF-59 (Chiron), the SBAS series of adjuvants (e.g., SBAS-2 or SBAS-4, available from SmithKline Beecham, Rixensart, Belgium), and Enhanzyn™ immunostimulant (Corixa, Hamilton, MT). Polyoxyethylene ether immunostimulants, are described in WO 99/52549A1.

The invention is further illustrated by the following non-limiting examples.

EXAMPLES

EXAMPLE 1

Preparation of *N*-[(*R*)-3-Tetradecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-Deoxy-4-*O*-phosphono-2-[(*R*)-3-tetradecanoyloxytetradecanoylamino]-3-*O*-[(*R*)-3-tetradecanoyloxytetradecanoyl]-β-D-glucopyranoside Triethylammonium Salt; triethylammonium salt of the compound of Formula (II)

(1a) To a solution of 2-deoxy-4-*O*-diphenylphosphono-3-*O*-[(*R*)-3-tetradecanoyloxytetradecanoyl]-6-*O*-(2,2,2-trichloro-1,1-dimethylethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)-β-D-glucopyranosyl bromide (1.05 g, 0.81 mmol) in dry 1,2-dichloroethane (10 mL) were added 4 Å molecular sieves (0.5 g), anhydrous CaSO₄ (2.2 g, 16 mmol), and *N*-[(*R*)-3-tetradecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinemethanol (0.40 g, 0.75 mmol). The resulting mixture was stirred for 1 h at room temperature, treated with Hg(CN)₂ (1.02 g, 4.05 mmol), and heated to reflux for 16 h in the dark. The cooled reaction mixture was diluted with CH₂Cl₂ and filtered. The filtrate was washed with 1 N aq KI, dried (Na₂SO₄), and concentrated. Flash chromatography on silica gel (gradient elution, 15→20% EtOAc/hexanes) afforded 0.605 g (43%) of *N*-[(*R*)-3-tetradecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-diphenylphosphono-3-*O*-[(*R*)-3-tetradecanoyloxytetradecanoyl]-6-*O*-(2,2,2-trichloro-

1,1-dimethylethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-glucopyranoside as an amorphous solid.

(1b) A solution of the compound prepared in (1a) above (0.50 g, 0.29 mmol) in AcOH (10 mL) at 60 °C was treated with zinc dust (0.98 g, 15 mmol) in three equal portions over a 1-h period. The cooled reaction mixture was sonicated, filtered through a pad of Celite, and concentrated. The resulting residue was partitioned between CH_2Cl_2 and saturated aq NaHCO_3 , and the layers were separated. The organic layer was dried (Na_2SO_4) and concentrated. A solution of the crude amino alcohol obtained and (*R*)-3-tetradecanoyloxytetradecanoic acid (0.155 g, 0.34 mmol) in CH_2Cl_2 (3.5 mL) was stirred with powdered 4 Å molecular sieves (0.25 g) for 0.5 h and then treated with 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (0.11 g, 0.44 mmol). The resulting mixture was stirred at room temperature for 8 h, filtered through Celite, and concentrated. Flash chromatography on silica gel with 50% EtOAc/hexanes gave 0.355 g (68%) of *N*-[(*R*)-3-tetradecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-diphenylphosphono-2-[(*R*)-3-tetradecanoyloxytetradecanoylamino]-3-*O*-[(*R*)-3-tetradecanoyloxytetradecanoyl]- β -D-glucopyranoside as a colorless syrup.

(1c) A solution of the compound prepared in (1b) above (0.300 g, 0.166 mmol) in a mixture of AcOH (1 mL) and tetrahydrofuran (9 mL) was hydrogenated in the presence of PtO_2 (0.15 g) at room temperature and 70 psig for 18 h. The reaction mixture was diluted with 2:1 CHCl_3 -MeOH (50 mL) and sonicated briefly. The catalyst was collected and washed with 2:1 CHCl_3 -MeOH and the combined filtrate and washings were concentrated. Flash chromatography on silica gel with CHCl_3 -MeOH- H_2O - Et_3N (90:10:0.5:0.5) gave partially purified product which was dissolved in ice-cold 2:1 CHCl_3 -MeOH (30 mL) and washed with ice-cold 0.1 N aq HCl (12 mL). The organic phase was filtered and lyophilized from 2% aq Et_3N (5 mL, pyrogen-free) to give 0.228 g (79%) of *N*-[(*R*)-3-tetradecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-phosphono-2-[(*R*)-3-tetradecanoyloxytetradecanoylamino]-3-*O*-[(*R*)-3-tetradecanoyloxytetradecanoyl]- β -D-glucopyranoside triethylammonium salt as a colorless powder: mp 67-70 °C; IR (film) 3306, 2955, 2923, 2853, 1736, 1732, 1644, 1548, 1466, 1378, 1245, 1177, 1110, 1053, 844 cm^{-1} ; ^1H NMR (CDCl_3 - CD_3OD) δ 0.88 (m, 18 H),

1.0–1.2.05 (mH), 2.20–2.70 (m, 12 H), 3.06 (q, 6 H, $J = 7.2$ Hz), 3.3–3.25 (mH), 4.52 (d, 1 H, $J = 8$ Hz), 5.05–5.28 (m, 4 H), 7.44 (d, 1 H, $J = 9$ Hz); ^{13}C NMR (CDCl_3) δ 173.3, 173.0, 170.3, 169.6, 168.6, 101.8, 100.4, 75.8, 72.5, 72.4, 70.9, 70.8, 70.3, 70.2, 69.9, 69.3, 67.9, 66.6, 56.5, 56.3, 54.5, 47.4, 45.8, 44.6, 41.4, 41.0, 39.7, 39.2, 39.0, 34.5, 34.3, 34.1, 32.0, 29.7, 29.4, 28.1, 27.3, 25.7, 25.3, 25.2, 25.1, 24.0, 22.7, 21.6, 14.1, 8.6.

Anal. Calcd. for $\text{C}_{101}\text{H}_{194}\text{N}_3\text{O}_{17}\text{P} \cdot \text{H}_2\text{O}$: C, 68.47; H, 11.15; N, 2.37; P, 1.75.

Found: C, 68.79; H, 11.00; N, 2.24; P, 1.97.

EXAMPLE 2

Preparation of *N*-[(*R*)-3-Dodecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-Deoxy-4-*O*-phosphono-2-[(*R*)-3-dodecanoyloxy-tetradecanoylamino]-3-*O*-[(*R*)-3-dodecanoyloxytetradecanoyl]- β -D-glucopyranoside Triethylammonium Salt); triethylammonium salt of Formula (III)

(2a) To a solution of 2-deoxy-4-*O*-diphenylphosphono-3-*O*-[(*R*)-3-dodecanoyloxytetradecanoyl]-6-*O*-(2,2,2-trichloro-1,1-dimethylethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)- α -D-glucopyranosyl bromide (1.60 g, 1.27 mmol) in dry 1,2-dichloroethane (3.2 mL) were added 4 Å molecular sieves (0.6 g), anhydrous CaSO_4 (1.0 g, 7.3 mmol), and *N*-[(*R*)-3-dodecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinemethanol (0.58 g, 1.14 mmol). The resulting mixture was stirred for 1 h at room temperature, treated with $\text{Hg}(\text{CN})_2$ (0.58 g, 2.3 mmol), and heated to reflux for 6 h in the dark. The cooled reaction mixture was diluted with CH_2Cl_2 and filtered through a bed of celite. The filtrate was washed with 1 N aq KI, dried (Na_2SO_4), and concentrated. Flash chromatography on silica gel (gradient elution, 25→35% EtOAc/hexanes) afforded 1.72 g (82%) of *N*-[(*R*)-3-dodecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-diphenylphosphono-3-*O*-[(*R*)-3-dodecanoyloxytetradecanoyl]-6-*O*-(2,2,2-trichloro-1,1-dimethylethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-glucopyranoside as a colorless oil.

(2b) A solution of the compound prepared in (2a) above (1.58 g, 0.806 mmol) in AcOH (40 mL) at 60 °C was treated with zinc dust (2.6 g, 40 mmol) in three equal portions over a 1-h period. The cooled reaction mixture was sonicated, filtered through a pad of Celite,

and concentrated. The resulting residue was partitioned between EtOAc and saturated aq NaHCO₃ and the layers separated. The organic layer was washed with brine, dried (Na₂SO₄), and concentrated to give 1.3 g of a white solid. A solution of the crude amino alcohol obtained and (*R*)-3-dodecanoyloxytetradecanoic acid (0.45 g, 1.05 mmol) in CH₂Cl₂ (20 mL) was treated with 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (0.30 g, 1.21 mmol). The resulting mixture was stirred at room temperature for 18 h and concentrated. Flash chromatography on silica gel with 40→50% EtOAc/hexanes gave 0.89 g (56%) of *N*-[(*R*)-3-dodecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-diphenylphosphono-2-[(*R*)-3-dodecanoyloxytetradecanoylamino]-3-*O*-[(*R*)-3-dodecanoyloxytetradecanoyl]-β-D-glucopyranoside as a white foam.

(2c) A solution of the compound prepared in (2b) above (0.75 g, 0.44 mmol) in a mixture of AcOH (4.5 mL) and tetrahydrofuran (45 mL) was hydrogenated in the presence of PtO₂ (0.45 g) at room temperature and 70 psig for 18 h. The reaction mixture was diluted with 2:1 CHCl₃-MeOH (35 mL) and sonicated briefly. The catalyst was collected and washed with 2:1 CHCl₃-MeOH and the combined filtrate and washings were concentrated. Flash chromatography on silica gel with CHCl₃-MeOH-H₂O-Et₃N (gradient elution; 96:4:0.3:0.3→90:10:0.5:0.5) gave partially purified product (0.51 g) which was dissolved in ice-cold 2:1 CHCl₃-MeOH (50 mL) and washed with ice-cold 0.1 N aq HCl (20 mL). The organic phase was filtered and concentrated. The white wax obtained was lyophilized from 2% aq Et₃N (70 mL, pyrogen-free) to give 0.54 g (78%) of *N*-[(*R*)-3-dodecanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-phosphono-2-[(*R*)-3-dodecanoyloxytetradecanoylamino]-3-*O*-[(*R*)-3-dodecanoyloxy-tetradecanoyl]-β-D-glucopyranoside triethylammonium salt as a white powder: mp 146-151 °C; IR (film) 3292, 3100, 2958, 2922, 2852, 1739, 1731, 1659, 1651, 1644, 1562, 1555, 1468, 1455, 1433, 1377, 1339, 1310, 1253, 1238, 1183, 1160, 1107, 1080, 1047, 960, 856, 722 cm⁻¹; ¹H NMR (CDCl₃-CD₃OD) δ 0.88 (m, 18 H), 1.0-2.10 (mH), 2.20-2.75 (m, 12 H), 3.04 (q, 6 H, *J* = 7.2 Hz), 3.3-4.3 (mH), 4.45 (d, 1 H, *J* = 8.5 Hz), 5.0-5.28 (m, 4 H); ¹³C NMR (CDCl₃) δ 173.9, 173.4, 173.2, 170.6, 170.1, 169.2, 101.4, 75.5, 74.0, 70.8, 70.7, 70.2, 68.5, 60.5, 56.6, 53.6, 47.4, 45.6, 40.9, 39.6, 38.8, 34.5, 34.3, 34.2, 34.1, 31.9, 29.7, 29.6, 29.5, 29.4, 29.4, 29.3, 29.2, 27.3, 25.2, 25.0, 23.6, 22.7, 21.6, 14.0, 8.3.

MALDI-MS calculated for $[M + Na]^+$ 1590.1900, found 1590.1866; Anal. Calculated for $C_{95}H_{182}N_3O_{17}P \cdot 3H_2O$: C, 66.20; H, 10.99; N, 2.44. Found: C, 66.36; H, 10.69; N, 2.15.

EXAMPLE 3

- 5 Preparation of *N*-[(*R*)-3-Decanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-Deoxy-4-*O*-phosphono-2-[(*R*)-3-Decanoyloxytetradecanoylamino]-3-*O*-[(*R*)-3-Decanoyloxytetradecanoyl]- β -D-glucopyranoside Triethylammonium Salt; triethylammonium salt of Formula (IV),

(3a) To a solution of 2-deoxy-4-*O*-diphenylphosphono-3-*O*-[(*R*)-3-decanoyloxytetradecanoyl]-6-*O*-(2,2,2-trichloro-1,1-dimethylethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)- α -D-glucopyranosyl bromide (1.70 g, 1.38 mmol) in dry 1,2-dichloroethane (3.5 mL) were added 4 Å molecular sieves (0.6 g), anhydrous $CaSO_4$ (1.2 g, 8.8 mmol), and *N*-[(*R*)-3-decanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinemethanol (0.60 g, 1.24 mmol). The resulting mixture was stirred for 1 h at room temperature, treated with $Hg(CN)_2$ (0.63 g, 2.5 mmol), and heated to reflux for 6 h in the dark. The cooled reaction mixture was diluted with CH_2Cl_2 and filtered through a bed of celite. The filtrate was washed with 1 N aq KI, dried (Na_2SO_4), and concentrated. Flash chromatography on silica gel (gradient elution, 25→40% EtOAc/hexanes) afforded 1.82 g (80%) of *N*-[(*R*)-3-decanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-diphenylphosphono-3-*O*-[(*R*)-3-decanoyloxytetradecanoyl]-6-*O*-(2,2,2-trichloro-1,1-dimethylethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamino)- β -D-glucopyranoside as a colorless oil.

(3b) A solution of the compound prepared in (3a) above (1.67 g, 1.02 mmol) in AcOH (50 mL) at 60 °C was treated with zinc dust (3.33 g, 51 mmol) in three equal portions over a 1-h period. The cooled reaction mixture was sonicated, filtered through a pad of Celite, and concentrated. The resulting residue was partitioned between EtOAc and saturated aq $NaHCO_3$ and the layers separated. The organic layer was washed with brine, dried (Na_2SO_4), and concentrated to give 1.25 g of a white solid. A solution of the crude amino alcohol obtained and (*R*)-3-decanoyloxytetradecanoic acid (0.53 g, 1.33 mmol) in CH_2Cl_2 (20 mL) was treated with 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline (0.38 g, 1.53 mmol). The resulting mixture was stirred at room temperature for 18 h and concentrated. Flash chromatography on

silica gel with 40→50% EtOAc/hexanes gave 1.23 g (74%) of *N*-[(*R*)-3-decanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-diphenylphosphono-2-[(*R*)-3-decanoyloxytetradecanoylamino]-3-*O*-[(*R*)-3-decanoyloxytetradecanoyl]-β-*D*-glucopyranoside as a white foam.

5 (3c) A solution of the compound prepared in (3b) above (1.07 g, 0.654 mmol) in a mixture of AcOH (6.5 mL) and tetrahydrofuran (65 mL) was hydrogenated in the presence of PtO₂ (0.66 g) at room temperature and 70 psig for 18 h. The reaction mixture was diluted with 2:1 CHCl₃-MeOH (50 mL) and sonicated briefly. The catalyst was collected and washed with 2:1 CHCl₃-MeOH and the combined filtrate and washings were concentrated. The resulting
10 waxy solid obtained was lyophilized from 2% aq triethylamine to give ~1 g of the crude triethylammonium salt as a white powder. Flash chromatography on silica gel with CHCl₃-MeOH-H₂O-Et₃N (gradient elution; 96:4:0.3:0.3→88:12:1:0.6) gave partially purified product (0.84 g) which was dissolved in ice-cold 2:1 CHCl₃-MeOH (168 mL) and washed with ice-cold 0.1 N aq HCl (67 mL). The organic phase was filtered and concentrated. The white wax
15 obtained (~0.7 g) was lyophilized from 2% aq Et₃N (70 mL, pyrogen-free) to give 0.79 g (79%) of *N*-[(*R*)-3-decanoyloxytetradecanoyl]-(*S*)-2-pyrrolidinylmethyl 2-deoxy-4-*O*-phosphono-2-[(*R*)-3-decanoyloxytetradecanoylamino]-3-*O*-[(*R*)-3-decanoyloxytetradecanoyl]-β-*D*-glucopyranoside triethylammonium salt as a white powder: mp 121-122 °C; IR (film) 3287, 3093, 2961, 2913, 2850, 1745, 1738, 1732, 1716, 1666, 1660, 1651, 1644, 1635, 1565, 1556,
20 1538, 1470, 1455, 1434, 1416, 1378, 1337, 1311, 1248, 1184, 1104, 1081, 1021, 964, 721 cm⁻¹; ¹H NMR (CDCl₃-CD₃OD) δ 0.88 (m, 18 H), 1.0-2.05 (mH), 2.20-2.75 (m, 12 H), 3.04 (q, 6 H, *J* = 7.2 Hz), 3.3-4.3 (mH), 4.45 (d, 1 H, *J* = 8.5 Hz), 5.0-5.28 (m, 4 H); ¹³C NMR (CDCl₃) δ 173.7, 173.4, 173.2, 170.5, 170.1, 169.1, 101.4, 75.6, 74.0, 70.8, 70.2, 68.7, 60.4, 56.6, 53.8, 47.4, 45.6, 41.0, 39.6, 38.9, 34.5, 34.3, 34.2, 34.1, 31.9, 29.7, 29.6, 29.5, 29.4, 29.4, 29.3, 29.2,
25 27.3, 25.3, 25.0, 23.7, 22.7, 21.6, 14.1, 8.4.

MALDI-MS calcd for [M + Na]⁺ 1506.0961, found 1506.1008; Anal. Calcd. for C₈₉H₁₇₀N₃O₁₇P: C, 67.43; H, 10.81; N, 2.65. Found: C, 67.26; H, 10.85; N, 2.47.

EXAMPLE 4

MURINE *LISTERIA MONOCYTOGENES* CHALLENGE MODEL

This example provides experiments evaluating the induction of non-specific resistance in the murine *Listeria monocytogenes* challenge model performed using the compounds prepared in examples 1, 2 and 3. Mice (5 per group) were treated intravenously with the 1 µg of a cyclic AGP or MPL solublized in 0.2% triethanolamine (TEOA). Two days later the mice were challenged intravenously with a $\sim 10^5$ *L. monocytogenes* 10403 serotype (stock culture provided by Jory Baldrige, Washington State University, Pullman, WA.). Two days after the challenge the mice were sacrificed and the number of colony forming units (CFUs) in the spleens of individual mice were determined by plating 10-fold serial dilutions of splenic homogenates on tryptic soy agar plates. The degree of protection afforded by a given AGP or MPL was calculated by subtracting the average number of bacteria per spleen (log₁₀ value) in the group of mice treated with a given compound, from the average number of bacteria per spleen (log₁₀ value) in a control group that was "sham" treated with vehicle (0.2% TEOA) prior to challenge with *L. monocytogenes*.

Of the compounds tested, that of Example 3 was the most active, inducing protection that was comparable to MPL (~ 0.9 log₁₀ units). The compound of example 2 induced slightly less protection and that of example 1 was the least protective, (0.7 and 0.2 log units, respectively).

EXAMPLE 5

PROTECTION AGAINST LETHAL INFLUENZA CHALLENGE BY
PROPHYLACTIC ADMINISTRATION OF CYCLIC AGPs

This example provides experiments evaluating protection against a lethal challenge with influenza in cyclic AGP-treated mice. BALB/c mice (10 mice per group) were treated intranasally with 20 µg of the compounds of examples 1, 2 and 3, or with MPL, 48 hours prior to an lethal intranasal challenge of Influenza A/HK/68 (5 LD₅₀). Protection was judged by

survival, observations of clinical symptoms (ruffled fur, hunched posture and labored breathing), and prevention of weight loss for 21 days following the challenge.

As was seen in the Listeria model, the compounds of examples 2 and 3 provided enhanced protection when compared with the vehicle control. Mice treated with the compound of example 3 had a 60% survival rate; those treated with the compound of example 2 had a 40% survival rate, and those with MPL, a 30% survival rate. No mice treated with the compound of example 1 survived. These data indicate that the compound of example 3 provided superior protection, followed by those of examples 2 and 1.

All publications and patent applications cited in this specification are herein incorporated by reference in their entirety. Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to those of ordinary skill in the art in light of the teachings of this invention that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims.